These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34423856)

  • 1. Structural Biology of LRRK2 and its Interaction with Microtubules.
    Leschziner AE; Reck-Peterson SL
    Mov Disord; 2021 Nov; 36(11):2494-2504. PubMed ID: 34423856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cell Biology of LRRK2 in Parkinson's Disease.
    Usmani A; Shavarebi F; Hiniker A
    Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.
    Sanz Murillo M; Villagran Suarez A; Dederer V; Chatterjee D; Alegrio Louro J; Knapp S; Mathea S; Leschziner AE
    Sci Adv; 2023 Dec; 9(48):eadk6191. PubMed ID: 38039358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The In Situ Structure of Parkinson's Disease-Linked LRRK2.
    Watanabe R; Buschauer R; Böhning J; Audagnotto M; Lasker K; Lu TW; Boassa D; Taylor S; Villa E
    Cell; 2020 Sep; 182(6):1508-1518.e16. PubMed ID: 32783917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2.
    Chen S; Basiashvili T; Hutchings J; Murillo MS; Suarez AV; Louro JA; Leschziner AE; Villa E
    bioRxiv; 2024 Jun; ():. PubMed ID: 38948781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
    Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S
    J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.
    Herbst S; Lewis PA
    Biochem J; 2021 Jul; 478(14):2945-2951. PubMed ID: 34328508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Coku I; Mutez E; Eddarkaoui S; Carrier S; Marchand A; Deldycke C; Goveas L; Baille G; Tir M; Magnez R; Thuru X; Vermeersch G; Vandenberghe W; Buée L; Defebvre L; Sablonnière B; Chartier-Harlin MC; Taymans JM; Huin V
    Mov Disord; 2022 Aug; 37(8):1761-1767. PubMed ID: 35708213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.
    Stormo AED; Shavarebi F; FitzGibbon M; Earley EM; Ahrendt H; Lum LS; Verschueren E; Swaney DL; Skibinski G; Ravisankar A; van Haren J; Davis EJ; Johnson JR; Von Dollen J; Balen C; Porath J; Crosio C; Mirescu C; Iaccarino C; Dauer WT; Nichols RJ; Wittmann T; Cox TC; Finkbeiner S; Krogan NJ; Oakes SA; Hiniker A
    J Cell Biol; 2022 Apr; 221(4):. PubMed ID: 35266954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the focal role of LRRK2 kinase in Parkinson's disease.
    Kumar S; Behl T; Sehgal A; Chigurupati S; Singh S; Mani V; Aldubayan M; Alhowail A; Kaur S; Bhatia S; Al-Harrasi A; Subramaniyan V; Fuloria S; Fuloria NK; Sekar M; Abdel Daim MM
    Environ Sci Pollut Res Int; 2022 May; 29(22):32368-32382. PubMed ID: 35147886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 recruitment, activity, and function in organelles.
    Bonet-Ponce L; Cookson MR
    FEBS J; 2022 Nov; 289(22):6871-6890. PubMed ID: 34196120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.